Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for TARS

Stock Name	Tarsus Pharmaceuticals Inc
Ticker	TARS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US87650L1035

Show aggregate TARS holdings

News associated with TARS

Blair William & Co. IL Trims Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Blair William & Co. IL decreased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 58.1% during the first quarter, Holdings Channel reports. The fund owned 11,416 shares of the company’s stock after selling 15,814 shares during the period. Blair William & Co. IL’s holdings in Tarsus Pharmaceuticals were worth $586,000 […] - 2025-08-11 05:52:54
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Buy” from Brokerages: Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have earned a consensus rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-08-06 03:06:50
Arizona State Retirement System Buys 470 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Arizona State Retirement System lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 6.1% during the first quarter, Holdings Channel.com reports. The firm owned 8,182 shares of the company’s stock after acquiring an additional 470 shares during the period. Arizona State Retirement System’s holdings in Tarsus Pharmaceuticals were worth $420,000 […] - 2025-07-23 05:44:46
Brokerages Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $66.67: Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to […] - 2025-06-20 02:36:52
GAMMA Investing LLC Purchases 13,115 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): GAMMA Investing LLC grew its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 36,430.6% in the first quarter, Holdings Channel reports. The fund owned 13,151 shares of the company’s stock after acquiring an additional 13,115 shares during the quarter. GAMMA Investing LLC’s holdings in Tarsus Pharmaceuticals were worth $676,000 at the end of […] - 2025-06-19 04:06:59
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 18.7% during the fourth quarter, HoldingsChannel reports. The fund owned 69,826 shares of the company’s stock after acquiring an additional 10,991 shares during the quarter. UBS AM a distinct […] - 2025-06-05 06:14:53
Nuveen Asset Management LLC Has $6.95 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Nuveen Asset Management LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 10.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 125,539 shares of the company’s stock after selling 15,186 shares during the quarter. Nuveen Asset […] - 2025-05-30 05:04:50
Tarsus Pharmaceuticals (NASDAQ:TARS) Raised to Buy at HC Wainwright: Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) was upgraded by equities research analysts at HC Wainwright to a “buy” rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a $72.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 71.22% from the […] - 2025-05-29 02:15:10
Two Sigma Advisers LP Has $2.96 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Two Sigma Advisers LP reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 79.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,500 shares of the company’s stock after selling 202,900 shares during the quarter. Two Sigma […] - 2025-05-28 07:09:12
Two Sigma Investments LP Has $5.05 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Two Sigma Investments LP lowered its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 69.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,171 shares of the company’s stock after selling 204,832 shares during the quarter. […] - 2025-05-28 05:04:57
Tarsus Pharmaceuticals (NASDAQ:TARS) and Dyadic International (NASDAQ:DYAI) Critical Survey: Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends. Earnings and Valuation This table compares Tarsus […] - 2025-05-27 02:17:08
Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Target Price at $66.33: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has earned an average recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation […] - 2025-05-26 03:08:58
Dimensional Fund Advisors LP Cuts Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Dimensional Fund Advisors LP reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 15.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 341,305 shares of the company’s stock after selling 62,658 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Tarsus Pharmaceuticals were worth $18,897,000 at […] - 2025-05-08 05:25:05
The Goldman Sachs Group Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock: Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) had its target price upped by investment analysts at The Goldman Sachs Group from $46.00 to $51.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of 9.80% from […] - 2025-05-07 02:22:52
Barclays PLC Sells 23,999 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Barclays PLC trimmed its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 24.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,664 shares of the company’s stock after selling 23,999 shares during the period. […] - 2025-04-28 05:01:20
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Legal & General Group Plc: Legal & General Group Plc trimmed its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 2.1% during the fourth quarter, Holdings Channel reports. The fund owned 26,595 shares of the company’s stock after selling 560 shares during the quarter. Legal & General Group Plc’s holdings in Tarsus Pharmaceuticals were worth $1,473,000 […] - 2025-04-27 05:42:58
Wells Fargo & Company MN Has $3.16 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Wells Fargo & Company MN raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 44.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 57,004 shares of the company’s stock after buying an additional 17,451 shares during the period. […] - 2025-04-24 04:32:51
Geode Capital Management LLC Buys 3,014 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Geode Capital Management LLC lifted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 0.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 838,804 shares of the company’s stock after buying an additional 3,014 shares during the quarter. Geode […] - 2025-04-15 05:00:56
Pictet Asset Management Holding SA Invests $284,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Pictet Asset Management Holding SA bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 5,130 shares of the company’s stock, valued at approximately $284,000. A number of other institutional investors and hedge funds have also recently bought and sold shares of the […] - 2025-04-11 06:24:52
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Vanguard Group Inc.: Vanguard Group Inc. boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 0.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,115,162 shares of the company’s stock after buying an additional 17,839 shares during the period. Vanguard Group Inc. owned 0.06% of Tarsus Pharmaceuticals worth $117,117,000 as […] - 2025-04-09 04:42:52
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up After Strong Earnings: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $45.54, but opened at $47.44. Tarsus Pharmaceuticals shares last traded at $44.83, with a volume of 251,757 shares. The company reported ($0.60) earnings per share […] - 2025-02-27 05:10:47
Allspring Global Investments Holdings LLC Has $10.03 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Allspring Global Investments Holdings LLC cut its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 181,122 shares of the company’s stock after selling 29,409 shares during the period. Allspring […] - 2025-02-19 07:08:18
Bleakley Financial Group LLC Makes New $323,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) in the fourth quarter, Holdings Channel reports. The firm bought 5,825 shares of the company’s stock, valued at approximately $323,000. A number of other large investors have also recently added to or reduced their stakes in the […] - 2025-02-12 06:57:10
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of “Buy” from Brokerages: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the […] - 2025-02-12 04:40:57
Tarsus Pharmaceuticals (NASDAQ:TARS) Given Buy Rating at Guggenheim: Guggenheim reissued their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) in a research report released on Monday morning,Benzinga reports. A number of other equities analysts have also weighed in on the stock. Barclays boosted their price objective on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an […] - 2025-02-11 05:09:04

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) TARS holdings

Date	Number of TARS Shares Held	Base Market Value of TARS Shares	Local Market Value of TARS Shares	Change in TARS Shares Held	Change in TARS Base Value	Current Price per TARS Share Held	Previous Price per TARS Share Held
2025-11-11 (Tuesday)	27,577	USD 2,085,924	USD 2,085,924	0	USD 78,594	USD 75.64	USD 72.79
2025-11-10 (Monday)	27,577	USD 2,007,330	USD 2,007,330	70	USD 129,977	USD 72.79	USD 68.25
2025-11-07 (Friday)	27,507	USD 1,877,353	USD 1,877,353	0	USD 4,401	USD 68.25	USD 68.09
2025-11-06 (Thursday)	27,507	USD 1,872,952	USD 1,872,952	70	USD 1,749	USD 68.09	USD 68.2
2025-11-05 (Wednesday)	27,437	USD 1,871,203	USD 1,871,203	0	USD -90,543	USD 68.2	USD 71.5
2025-11-04 (Tuesday)	27,437	USD 1,961,746	USD 1,961,746	71	USD 51,873	USD 71.5	USD 69.79
2025-11-03 (Monday)	27,366	USD 1,909,873	USD 1,909,873	0	USD 26,819	USD 69.79	USD 68.81
2025-10-31 (Friday)	27,366	USD 1,883,054	USD 1,883,054	0	USD -4,105	USD 68.81	USD 68.96
2025-10-30 (Thursday)	27,366	USD 1,887,159	USD 1,887,159	355	USD 63,376	USD 68.96	USD 67.52
2025-10-29 (Wednesday)	27,011	USD 1,823,783	USD 1,823,783	142	USD 8,513	USD 67.52	USD 67.56
2025-10-28 (Tuesday)	26,869	USD 1,815,270	USD 1,815,270	0	USD -16,255	USD 67.56	USD 68.165
2025-10-27 (Monday)	26,869	USD 1,831,525	USD 1,831,525	0	USD 56,559	USD 68.165	USD 66.06

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of TARS by Blackrock for IE00BDZVHG35

Show aggregate share trades of TARS

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 70 72.790* 49.19
2025-11-06 BUY 70 68.090* 48.98
2025-11-04 BUY 71 71.500* 48.75
2025-10-30 BUY 355 70.070 67.000 67.307 USD 23,894 48.41
2025-10-29 BUY 142 67.520 69.325 69.144 USD 9,819 48.30
2025-10-22 SELL -284 68.700 70.445 70.270 USD -19,957 47.74 Loss of -6,399 on sale
2025-10-20 BUY 142 71.190 74.850 74.484 USD 10,577 47.47
2025-10-17 BUY 354 72.930 74.815 74.627 USD 26,418 47.32
2025-10-15 BUY 560 74.950 75.010 75.004 USD 42,002 47.15
2025-10-03 BUY 483 65.170 65.970 65.890 USD 31,825 46.91
2025-10-02 BUY 69 58.770 59.510 59.436 USD 4,101 46.84
2025-09-30 BUY 138 59.430 59.770 59.736 USD 8,244 46.70
2025-09-26 BUY 138 56.290 56.481 56.462 USD 7,792 46.57
2025-09-25 BUY 138 55.390 56.250 56.164 USD 7,751 46.51
2025-09-18 BUY 72 54.025 54.360 54.327 USD 3,912 46.47
2025-09-17 BUY 216 51.690 52.400 52.329 USD 11,303 46.43
2025-07-17 SELL -144 41.400 41.855 41.809 USD -6,021 46.49 Profit of 674 on sale
2025-07-11 SELL -576 39.180 41.005 40.823 USD -23,514 46.64 Profit of 3,352 on sale
2025-07-02 BUY 3,960 40.450 41.060 40.999 USD 162,356 46.79
2025-06-25 BUY 144 40.200 42.000 41.820 USD 6,022 46.97
2025-06-20 BUY 2,205 40.650 41.300 41.235 USD 90,923 47.11
2025-06-11 BUY 130 40.960 42.125 42.008 USD 5,461 47.44
2025-06-10 BUY 130 41.170 44.085 43.793 USD 5,693 47.48
2025-06-04 SELL -64 42.650 44.520 44.333 USD -2,837 47.61 Profit of 210 on sale
2025-04-23 BUY 64 50.000 51.000 50.900 USD 3,258 48.21
2025-04-10 SELL -512 44.120 44.870 44.795 USD -22,935 48.20 Profit of 1,746 on sale
2025-04-08 SELL -64 44.630 49.005 48.568 USD -3,108 48.27 Loss of -19 on sale
2025-04-07 SELL -64 47.490 49.040 48.885 USD -3,129 48.28 Loss of -39 on sale
2025-04-04 SELL -320 47.020 48.800 48.622 USD -15,559 48.30 Loss of -104 on sale
2025-04-01 BUY 709 48.920 51.330 51.089 USD 36,222 48.25
2025-03-31 SELL -189 51.370 51.630 51.604 USD -9,753 48.21 Loss of -641 on sale
2025-03-21 BUY 892 49.970 51.140 51.023 USD 45,513 47.98
2025-03-14 SELL -960 48.090 48.230 48.216 USD -46,287 47.96 Loss of -246 on sale
2025-03-07 SELL -120 46.470 46.770 46.740 USD -5,609 48.08 Profit of 161 on sale
2025-03-04 SELL -60 44.500 45.680 45.562 USD -2,734 48.27 Profit of 162 on sale
2025-02-25 BUY 120 41.290 47.630 46.996 USD 5,640 48.73
2025-02-19 SELL -60 49.550 50.660 50.549 USD -3,033 48.79 Loss of -106 on sale
2025-02-13 BUY 180 52.230 53.220 53.121 USD 9,562 48.62
2025-02-12 BUY 60 52.330 52.970 52.906 USD 3,174 48.54
2025-02-11 BUY 240 51.220 52.005 51.927 USD 12,462 48.49
2024-12-30 SELL -1,870 54.700 57.140 56.896 USD -106,396 46.51 Loss of -19,413 on sale
2024-11-18 SELL -975 44.630 46.790 46.574 USD -45,410 43.39 Loss of -3,103 on sale
2024-11-08 SELL -65 49.420 49.900 49.852 USD -3,240 42.66 Loss of -467 on sale
2024-10-21 SELL -65 36.450 36.820 36.783 USD -2,391 0.00 Loss of -2,391 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	70			72.790*		49.19
2025-11-06	BUY	70			68.090*		48.98
2025-11-04	BUY	71			71.500*		48.75
2025-10-30	BUY	355	70.070	67.000	67.307	USD 23,894	48.41
2025-10-29	BUY	142	67.520	69.325	69.144	USD 9,819	48.30
2025-10-22	SELL	-284	68.700	70.445	70.270	USD -19,957	47.74 Loss of -6,399 on sale
2025-10-20	BUY	142	71.190	74.850	74.484	USD 10,577	47.47
2025-10-17	BUY	354	72.930	74.815	74.627	USD 26,418	47.32
2025-10-15	BUY	560	74.950	75.010	75.004	USD 42,002	47.15
2025-10-03	BUY	483	65.170	65.970	65.890	USD 31,825	46.91
2025-10-02	BUY	69	58.770	59.510	59.436	USD 4,101	46.84
2025-09-30	BUY	138	59.430	59.770	59.736	USD 8,244	46.70
2025-09-26	BUY	138	56.290	56.481	56.462	USD 7,792	46.57
2025-09-25	BUY	138	55.390	56.250	56.164	USD 7,751	46.51
2025-09-18	BUY	72	54.025	54.360	54.327	USD 3,912	46.47
2025-09-17	BUY	216	51.690	52.400	52.329	USD 11,303	46.43
2025-07-17	SELL	-144	41.400	41.855	41.809	USD -6,021	46.49 Profit of 674 on sale
2025-07-11	SELL	-576	39.180	41.005	40.823	USD -23,514	46.64 Profit of 3,352 on sale
2025-07-02	BUY	3,960	40.450	41.060	40.999	USD 162,356	46.79
2025-06-25	BUY	144	40.200	42.000	41.820	USD 6,022	46.97
2025-06-20	BUY	2,205	40.650	41.300	41.235	USD 90,923	47.11
2025-06-11	BUY	130	40.960	42.125	42.008	USD 5,461	47.44
2025-06-10	BUY	130	41.170	44.085	43.793	USD 5,693	47.48
2025-06-04	SELL	-64	42.650	44.520	44.333	USD -2,837	47.61 Profit of 210 on sale
2025-04-23	BUY	64	50.000	51.000	50.900	USD 3,258	48.21
2025-04-10	SELL	-512	44.120	44.870	44.795	USD -22,935	48.20 Profit of 1,746 on sale
2025-04-08	SELL	-64	44.630	49.005	48.568	USD -3,108	48.27 Loss of -19 on sale
2025-04-07	SELL	-64	47.490	49.040	48.885	USD -3,129	48.28 Loss of -39 on sale
2025-04-04	SELL	-320	47.020	48.800	48.622	USD -15,559	48.30 Loss of -104 on sale
2025-04-01	BUY	709	48.920	51.330	51.089	USD 36,222	48.25
2025-03-31	SELL	-189	51.370	51.630	51.604	USD -9,753	48.21 Loss of -641 on sale
2025-03-21	BUY	892	49.970	51.140	51.023	USD 45,513	47.98
2025-03-14	SELL	-960	48.090	48.230	48.216	USD -46,287	47.96 Loss of -246 on sale
2025-03-07	SELL	-120	46.470	46.770	46.740	USD -5,609	48.08 Profit of 161 on sale
2025-03-04	SELL	-60	44.500	45.680	45.562	USD -2,734	48.27 Profit of 162 on sale
2025-02-25	BUY	120	41.290	47.630	46.996	USD 5,640	48.73
2025-02-19	SELL	-60	49.550	50.660	50.549	USD -3,033	48.79 Loss of -106 on sale
2025-02-13	BUY	180	52.230	53.220	53.121	USD 9,562	48.62
2025-02-12	BUY	60	52.330	52.970	52.906	USD 3,174	48.54
2025-02-11	BUY	240	51.220	52.005	51.927	USD 12,462	48.49
2024-12-30	SELL	-1,870	54.700	57.140	56.896	USD -106,396	46.51 Loss of -19,413 on sale
2024-11-18	SELL	-975	44.630	46.790	46.574	USD -45,410	43.39 Loss of -3,103 on sale
2024-11-08	SELL	-65	49.420	49.900	49.852	USD -3,240	42.66 Loss of -467 on sale
2024-10-21	SELL	-65	36.450	36.820	36.783	USD -2,391	0.00 Loss of -2,391 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of TARS

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	252,801	0	426,166	59.3%
2025-09-18	137,976	0	230,324	59.9%
2025-09-17	350,436	5	543,379	64.5%
2025-09-16	169,762	23	341,917	49.7%
2025-09-15	188,220	0	351,011	53.6%
2025-09-12	173,824	19	536,802	32.4%
2025-09-11	254,169	0	587,029	43.3%
2025-09-10	130,049	21,726	202,273	64.3%
2025-09-09	81,081	0	152,616	53.1%
2025-09-08	127,262	13,834	268,329	47.4%
2025-09-05	111,598	0	279,260	40.0%
2025-09-04	157,740	6,413	224,745	70.2%
2025-09-03	72,242	1,200	191,629	37.7%
2025-09-02	219,449	0	325,874	67.3%
2025-08-29	62,133	0	140,050	44.4%
2025-08-28	50,541	0	159,808	31.6%
2025-08-27	36,919	0	92,543	39.9%
2025-08-26	63,628	0	154,058	41.3%
2025-08-25	72,109	0	148,872	48.4%
2025-08-22	80,786	0	201,829	40.0%
2025-08-21	73,646	0	231,979	31.7%
2025-08-20	93,401	891	221,733	42.1%
2025-08-19	42,418	0	137,197	30.9%
2025-08-18	116,541	20,164	304,699	38.2%
2025-08-15	133,688	400	335,133	39.9%
2025-08-14	81,791	328	173,473	47.1%
2025-08-13	119,902	0	340,392	35.2%
2025-08-12	113,528	0	262,067	43.3%
2025-08-11	247,112	200	586,919	42.1%
2025-08-08	164,594	0	266,105	61.9%
2025-08-07	425,029	300	765,615	55.5%
2025-08-06	173,644	39	252,868	68.7%
2025-08-05	89,019	5	111,443	79.9%
2025-08-04	104,357	20	207,097	50.4%
2025-08-01	273,972	0	370,178	74.0%
2025-07-31	170,413	0	271,101	62.9%
2025-07-30	92,228	0	317,929	29.0%
2025-07-29	142,684	0	285,141	50.0%
2025-07-28	123,438	31	191,764	64.4%
2025-07-25	123,025	336	162,520	75.7%
2025-07-24	122,485	10	171,350	71.5%
2025-07-23	115,791	0	149,653	77.4%
2025-07-22	84,089	10	133,731	62.9%
2025-07-21	196,108	151	244,905	80.1%
2025-07-18	290,801	482	509,804	57.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE